Cargando…

Temporal trends and regional disparities in cancer screening utilization: an observational Swiss claims-based study

BACKGROUND: We examined colorectal, breast, and prostate cancer screening utilization in eligible populations within three data cross-sections, and identified factors potentially modifying cancer screening utilization in Swiss adults. METHODS: The study is based on health insurance claims data of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bähler, Caroline, Brüngger, Beat, Ulyte, Agne, Schwenkglenks, Matthias, von Wyl, Viktor, Dressel, Holger, Gruebner, Oliver, Wei, Wenjia, Blozik, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786957/
https://www.ncbi.nlm.nih.gov/pubmed/33402140
http://dx.doi.org/10.1186/s12889-020-10079-8
_version_ 1783632733165060096
author Bähler, Caroline
Brüngger, Beat
Ulyte, Agne
Schwenkglenks, Matthias
von Wyl, Viktor
Dressel, Holger
Gruebner, Oliver
Wei, Wenjia
Blozik, Eva
author_facet Bähler, Caroline
Brüngger, Beat
Ulyte, Agne
Schwenkglenks, Matthias
von Wyl, Viktor
Dressel, Holger
Gruebner, Oliver
Wei, Wenjia
Blozik, Eva
author_sort Bähler, Caroline
collection PubMed
description BACKGROUND: We examined colorectal, breast, and prostate cancer screening utilization in eligible populations within three data cross-sections, and identified factors potentially modifying cancer screening utilization in Swiss adults. METHODS: The study is based on health insurance claims data of the Helsana Group. The Helsana Group is one of the largest health insurers in Switzerland, insuring approximately 15% of the entire Swiss population across all regions and age groups. We assessed proportions of the eligible populations receiving colonoscopy/fecal occult blood testing (FOBT), mammography, or prostate-specific antigen (PSA) testing in the years 2014, 2016, and 2018, and calculated average marginal effects of individual, temporal, regional, insurance-, supply-, and system-related variables on testing utilization using logistic regression. RESULTS: Overall, 8.3% of the eligible population received colonoscopy/FOBT in 2014, 8.9% in 2016, and 9.2% in 2018. In these years, 20.9, 21.2, and 20.4% of the eligible female population received mammography, and 30.5, 31.1, and 31.8% of the eligible male population had PSA testing. Adjusted testing utilization varied little between 2014 and 2018; there was an increasing trend of 0.8% (0.6–1.0%) for colonoscopy/FOBT and of 0.5% (0.2–0.8%) for PSA testing, while mammography use decreased by 1.5% (1.2–1.7%). Generally, testing utilization was higher in French-speaking and Italian-speaking compared to German-speaking region for all screening types. Cantonal programs for breast cancer screening were associated with an increase of 7.1% in mammography utilization. In contrast, a high density of relevant specialist physicians showed null or even negative associations with screening utilization. CONCLUSIONS: Variation in cancer screening utilization was modest over time, but considerable between regions. Regional variation was highest for mammography use where recommendations are debated most controversially, and the implementation of programs differed the most. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-020-10079-8.
format Online
Article
Text
id pubmed-7786957
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77869572021-01-07 Temporal trends and regional disparities in cancer screening utilization: an observational Swiss claims-based study Bähler, Caroline Brüngger, Beat Ulyte, Agne Schwenkglenks, Matthias von Wyl, Viktor Dressel, Holger Gruebner, Oliver Wei, Wenjia Blozik, Eva BMC Public Health Research Article BACKGROUND: We examined colorectal, breast, and prostate cancer screening utilization in eligible populations within three data cross-sections, and identified factors potentially modifying cancer screening utilization in Swiss adults. METHODS: The study is based on health insurance claims data of the Helsana Group. The Helsana Group is one of the largest health insurers in Switzerland, insuring approximately 15% of the entire Swiss population across all regions and age groups. We assessed proportions of the eligible populations receiving colonoscopy/fecal occult blood testing (FOBT), mammography, or prostate-specific antigen (PSA) testing in the years 2014, 2016, and 2018, and calculated average marginal effects of individual, temporal, regional, insurance-, supply-, and system-related variables on testing utilization using logistic regression. RESULTS: Overall, 8.3% of the eligible population received colonoscopy/FOBT in 2014, 8.9% in 2016, and 9.2% in 2018. In these years, 20.9, 21.2, and 20.4% of the eligible female population received mammography, and 30.5, 31.1, and 31.8% of the eligible male population had PSA testing. Adjusted testing utilization varied little between 2014 and 2018; there was an increasing trend of 0.8% (0.6–1.0%) for colonoscopy/FOBT and of 0.5% (0.2–0.8%) for PSA testing, while mammography use decreased by 1.5% (1.2–1.7%). Generally, testing utilization was higher in French-speaking and Italian-speaking compared to German-speaking region for all screening types. Cantonal programs for breast cancer screening were associated with an increase of 7.1% in mammography utilization. In contrast, a high density of relevant specialist physicians showed null or even negative associations with screening utilization. CONCLUSIONS: Variation in cancer screening utilization was modest over time, but considerable between regions. Regional variation was highest for mammography use where recommendations are debated most controversially, and the implementation of programs differed the most. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-020-10079-8. BioMed Central 2021-01-05 /pmc/articles/PMC7786957/ /pubmed/33402140 http://dx.doi.org/10.1186/s12889-020-10079-8 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Bähler, Caroline
Brüngger, Beat
Ulyte, Agne
Schwenkglenks, Matthias
von Wyl, Viktor
Dressel, Holger
Gruebner, Oliver
Wei, Wenjia
Blozik, Eva
Temporal trends and regional disparities in cancer screening utilization: an observational Swiss claims-based study
title Temporal trends and regional disparities in cancer screening utilization: an observational Swiss claims-based study
title_full Temporal trends and regional disparities in cancer screening utilization: an observational Swiss claims-based study
title_fullStr Temporal trends and regional disparities in cancer screening utilization: an observational Swiss claims-based study
title_full_unstemmed Temporal trends and regional disparities in cancer screening utilization: an observational Swiss claims-based study
title_short Temporal trends and regional disparities in cancer screening utilization: an observational Swiss claims-based study
title_sort temporal trends and regional disparities in cancer screening utilization: an observational swiss claims-based study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786957/
https://www.ncbi.nlm.nih.gov/pubmed/33402140
http://dx.doi.org/10.1186/s12889-020-10079-8
work_keys_str_mv AT bahlercaroline temporaltrendsandregionaldisparitiesincancerscreeningutilizationanobservationalswissclaimsbasedstudy
AT brunggerbeat temporaltrendsandregionaldisparitiesincancerscreeningutilizationanobservationalswissclaimsbasedstudy
AT ulyteagne temporaltrendsandregionaldisparitiesincancerscreeningutilizationanobservationalswissclaimsbasedstudy
AT schwenkglenksmatthias temporaltrendsandregionaldisparitiesincancerscreeningutilizationanobservationalswissclaimsbasedstudy
AT vonwylviktor temporaltrendsandregionaldisparitiesincancerscreeningutilizationanobservationalswissclaimsbasedstudy
AT dresselholger temporaltrendsandregionaldisparitiesincancerscreeningutilizationanobservationalswissclaimsbasedstudy
AT gruebneroliver temporaltrendsandregionaldisparitiesincancerscreeningutilizationanobservationalswissclaimsbasedstudy
AT weiwenjia temporaltrendsandregionaldisparitiesincancerscreeningutilizationanobservationalswissclaimsbasedstudy
AT blozikeva temporaltrendsandregionaldisparitiesincancerscreeningutilizationanobservationalswissclaimsbasedstudy